ADVFN US – Market Content Editor
-
United Therapeutics shares jump after positive results from Tyvaso trial
Shares of United Therapeutics Corporation (NASDAQ:UTHR) climbed about 12% on Monday after the company reported that its pivotal TETON-1 study of Tyvaso successfully achieved its primary endpoint in patients with idiopathic pulmonary fibrosis (IPF). The inhaled therapy demonstrated clear superiority over placebo in improving absolute forced vital capacity, showing a treatment difference of 130.1 mL.…
-
Avis Budget shares slide after company unveils equity distribution plan
Shares of Avis Budget Group (NASDAQ:CAR) dropped about 10% on Monday after the company disclosed that it had entered into an Equity Distribution Agreement with a group of major investment banks. Under the agreement, dated March 27, 2026, Avis Budget has the option to sell up to 5,000,000 shares of its common stock through a…
-
Royalty Pharma signs $500M co-development agreement with J&J
Royalty Pharma plc (NASDAQ:RPRX) said it has entered into a research and development co-funding agreement with Johnson & Johnson (NYSE:JNJ) valued at $500 million to support the development of JNJ-4804, an experimental treatment for autoimmune diseases. The funding will be provided over the 2026–2027 period. JNJ-4804 is described as a novel co-antibody therapy designed to…
-
Sight Sciences wins $34M patent ruling against Alcon
Sight Sciences Inc. (NASDAQ:SGHT) has obtained a court order confirming a jury’s finding that Alcon Inc. willfully infringed three patents related to glaucoma treatment technology. The order was issued on March 27, 2026, by the U.S. District Court for the District of Delaware. The ruling grants Sight Sciences $34 million in damages. This includes $5.5…
-
Sysco shares slip after report of $29B Restaurant Depot acquisition
Shares of Sysco Corp (NYSE:SYY) fell more than 2% in premarket trading on Monday after a Bloomberg report said the food distribution giant is close to acquiring family-owned Restaurant Depot in a transaction valued at about $29 billion, including debt. According to the report, Restaurant Depot shareholders would receive $21.6 billion in cash along with…
-
Palo Alto shares gain after CEO buys $10 million worth of stock
Shares of Palo Alto Networks (NASDAQ:PANW) climbed about 2% in premarket trading on Monday after Chief Executive Officer Nikesh Arora disclosed that he had purchased $10 million of company shares on the open market. The disclosure, released after the close of trading on Friday, came during a broader decline in cybersecurity stocks. Palo Alto’s shares…
-
Five market themes investors will be watching this week
The conflict involving Iran is expected to remain a key focus for investors during a shortened trading week on Wall Street. U.S. President Donald Trump has suggested that discussions with Tehran have made progress, even as the fighting continues to expand across the Middle East. Oil prices remain far above the levels seen before the…
-
iPhone demand remains resilient in China despite weaker smartphone shipments, report says
Apple’s (NASDAQ:AAPL) iPhone continues to outperform Android competitors in China even as overall smartphone shipments decline, with Android brands facing rising inventory levels and increasing prices, according to a Jefferies report citing February data from China’s Ministry of Industry and Information Technology (MIIT). Total smartphone shipments in China dropped 12.6% year-on-year in February after a…
-
Eli Lilly strikes $2.75 billion drug discovery partnership with InSilico
Eli Lilly (NYSE:LLY) has entered into a drug discovery collaboration with Hong Kong-listed InSilico that could be worth up to $2.75 billion, the companies said on Sunday. As part of the agreement, InSilico will receive an upfront payment of $115 million. The company may also earn additional milestone payments that could lift the total value…
-
J&J reports one-year ICOTYDE psoriasis trial results show sustained efficacy
Johnson & Johnson (NYSE:JNJ) has released one-year results from Phase 3 clinical trials indicating that its psoriasis treatment ICOTYDE maintained strong skin clearance outcomes through 52 weeks. Data from the ICONIC-ADVANCE 1 and 2 trials showed that complete skin clearance rates improved over time. In the studies, clearance increased from 41% to 49% and from…